BioCentury | Jan 7, 2020

BioIntervene takes on adenosine in pain, raises $30M

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic. The company plans to...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Dec 20, 2012
Targets & Mechanisms

Targeting interleukins in Alzheimer's disease

Researchers at Charité-University Hospital Berlin and the University of Zurich have data showing that p40, a protein subunit shared by IL-12 and IL-23 , could be a new therapeutic target in Alzheimer's disease. 1 The group...
BC Innovations | Nov 1, 2012
Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Adenosine A2 receptor (ADORA2) In vitro and mouse studies suggest ADORA2 agonist-treated dendritic cells (DCs) could help treat acute kidney injury. Mice...
BC Innovations | Jun 14, 2012
Targets & Mechanisms

Beta testing adenosine receptor agonists

Researchers at the University of California, San Francisco have used a zebrafish screen to identify an adenosine receptor agonist that improved both b cell regeneration and glucose control in diabetic mice. 1 The discovery could...
BC Innovations | Oct 6, 2011
Cover Story

Opening the brain

A Cornell University team has proposed a new strategy for delivering large-molecule therapeutics into the CNS: agonizing adenosine receptors in the brain's vasculature to loosen up the blood brain barrier. 1 Private equity company KensaGroup...
BC Week In Review | Sep 19, 2011
Clinical News

OPA-6566: Phase I/II started

Acucela Inc. (Seattle, Wash.) began a single-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial in about 120 patients comparing OPA-6566 vs. daily latanoprost. Patients will receive OPA-6566 daily for 2 weeks and twice daily for an...
BC Innovations | Jan 20, 2011
Cover Story

Two edges of sickle cell disease

A U.S.-China team has shown that inhibiting signaling between adenosine and the adenosine A 2B receptor in blood could prevent vaso-occlusion and consequent organ damage in sickle cell disease. 1 The researchers already are in...
BC Innovations | Oct 15, 2009
Cover Story

A gut feeling for CD39

Researchers have reported that enhancing CD39 activity in the gut could trigger a T reg -mediated immunosuppressive response to help treat inflammatory bowel disease. 1 The researchers are now developing a soluble form of CD39...
BC Week In Review | May 18, 2009
Clinical News

Acadesine: Phase III started

Schering-Plough began the double-blind, placebo-controlled, international Phase III RED-CABG trial to evaluate 42 mg/kg IV acadesine given over 7 hours in 7,500 patients. Administration will begin within 30 minutes of the induction of anesthesia and...
Items per page:
1 - 10 of 21